BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 4201309)

  • 1. Formulation of three nitrosoureas for intravenous use.
    Davignon JP; Yang KW; Wood HB; Cradock JC
    Cancer Chemother Rep 3; 1973 May; 4(3):7-11. PubMed ID: 4201309
    [No Abstract]   [Full Text] [Related]  

  • 2. Nitrosoureas in central nervous system tumors.
    Walker MD
    Cancer Chemother Rep 3; 1973 May; 4(3):21-6. PubMed ID: 4584033
    [No Abstract]   [Full Text] [Related]  

  • 3. Current status of new agents.
    Carter SK
    Cancer Chemother Rep 3; 1972 May; 3(1):33-47. PubMed ID: 4116662
    [No Abstract]   [Full Text] [Related]  

  • 4. 3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity.
    Schein PS; McMenamin MG; Anderson T
    Cancer Res; 1973 Sep; 33(9):2005-9. PubMed ID: 4353476
    [No Abstract]   [Full Text] [Related]  

  • 5. 1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
    Carter SK; Schabel FM; Broder LE; Johnston TP
    Adv Cancer Res; 1972; 16():273-332. PubMed ID: 4563045
    [No Abstract]   [Full Text] [Related]  

  • 6. Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.
    Wheeler GP; Bowdon BJ; Grimsley JA; Lloyd HH
    Cancer Res; 1974 Jan; 34(1):194-200. PubMed ID: 4809457
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumour activity of a new water-soluble nitrosoureido sugar: CY233 (NSC 609224).
    Gosse C; Atassi G; Letourneux Y; Ardouin P; Gouyette A; Fournier JP; Roger P
    Anticancer Res; 1988; 8(6):1419-22. PubMed ID: 3218975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems.
    Johnston TP; Montgomery JA
    Cancer Treat Rep; 1986 Jan; 70(1):13-30. PubMed ID: 2935250
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy of advanced gastrointestinal cancer with the nitrosoureas.
    Moertel CG
    Cancer Chemother Rep 3; 1973 May; 4(3):27-34. PubMed ID: 4748872
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of the status of the nitrosoureas in other tumors.
    Carter SK
    Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
    [No Abstract]   [Full Text] [Related]  

  • 11. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 12. Early history and development of the nitrosoureas.
    Schepartz SA
    Cancer Treat Rep; 1976 Jun; 60(6):647-9. PubMed ID: 782693
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
    Hansch C; Leo A; Schmidt C; Jow PY; Montgomery JA
    J Med Chem; 1980 Oct; 23(10):1095-101. PubMed ID: 7420354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicology and pharmacology of the nitrosoureas.
    Oliverio VT
    Cancer Chemother Rep 3; 1973 May; 4(3):13-20. PubMed ID: 4201308
    [No Abstract]   [Full Text] [Related]  

  • 16. Contributions of nitrosoureas to cancer treatment.
    Mitchell EP; Schein PS
    Cancer Treat Rep; 1986 Jan; 70(1):31-41. PubMed ID: 3002621
    [No Abstract]   [Full Text] [Related]  

  • 17. Historical development and future promise of the nitrosoureas as anticancer agents.
    Schabel FM
    Cancer Chemother Rep 3; 1973 May; 4(3):3-6. PubMed ID: 4584035
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and antitumour activity of several new 4-aroyl-1-nitrosohydrazinecarboxamides.
    Gugova R; Topakbashian V; Lozeva S; Dimov S; Golovinsky E
    Drugs Exp Clin Res; 1997; 23(2):71-5. PubMed ID: 9309382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fat emulsion vehicle for intravenous administration of an aqueous insoluble drug.
    Fortner CL; Grove WR; Bowie D; Walker MD
    Am J Hosp Pharm; 1975 Jun; 32(6):582-4. PubMed ID: 1155469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experimental studies on oral administration of nitrosourea anti-tumor agent, MCNU].
    Sekido S; Ninomiya K; Araki T; Ueno M; Kinbara M
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1492-500. PubMed ID: 6234861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.